The largest increase in cancer diagnosis at age 65 years was in stage I for all breast cancer, colon cancer, prostate cancer, and lung cancer.
Black men were less likely to receive androgen deprivation therapy and had lower use of secondary treatment with radiotherapy.
Investigators compared the efficacy, safety, and costs of abiraterone, darolutamide, enzalutamide, and apalutamide in treating nmCRPC.
The technical challenges and potential complications of extended PLND warrant careful consideration, according to investigators.
Patients’ risk of pathologic upgrading may depend on their intermediate-risk factor (Gleason score 3+4, PSA level of 10-20 ng/mL, and cT2b-c disease).